Methods of treating heavy menstrual bleeding
AssigneeAbbVie Inc.
InventorsJuki Wing-Keung Ng, Mohamad Shebley
Life of this patent
Estimating the term…
Abstract
The present invention relates to the method of treating heavy menstrual bleeding in a subject with or without uterine fibroids and in need of treatment by administering an effective amount of 4-((R)-2-[5-(2-fluoro-3-methoxy-phenyl)-3-(2-fluoro-6-trifluoromethyl-benzyl)-4-methyl-2,6-dioxo-3,6-dihydro-2H-pyrimidin-1-yl]-1-phenyl-ethylamino)-butyric acid or a pharmaceutically acceptable salt thereof, in combination with estrogens and progestogens.
Claims2
A method of managing moderate to severe pain associated with endometriosis in a premenopausal adult human female patient suffering from endometriosis and having hepatic impairment classified as Child-Pugh B, the method comprising:
- providing a tablet comprising 155.2 mg or 207.0 mg of a sodium salt of 4-((R)-2-[5-(2-fluoro-3-methoxy-phenyl)-3-(2-fluoro-6-trifluoromethyl-benzyl)-4-methyl-2,6-dioxo-3,6-dihydro-2H-pyrimidin-1-yl]-1-phenyl-ethylamino)-butyric acid (“elagolix sodium”),
- measuring hepatic function of the patient and determining that the patient has hepatic impairment classified as Child-Pugh B,
- orally administering the tablet comprising 155.2 mg of elagolix sodium to said patient having hepatic impairment classified as Child-Pugh B once daily for up to 6 months;
- wherein said method manages the moderate to severe pain associated with endometriosis in the patient.
A method of managing moderate to severe pain associated with endometriosis in a premenopausal adult human female patient suffering from endometriosis and having hepatic impairment classified as Child-Pugh B, the method comprising:
- oral administration of a tablet comprising 155.2 mg of a sodium salt of 4-((R)-2-[5-(2-fluoro-3-methoxy-phenyl)-3-(2-fluoro-6-trifluoromethyl-benzyl)-4-methyl-2,6-dioxo-3,6-dihydro-2H-pyrimidin-1-yl]-1-phenyl-ethylamino)-butyric acid (“elagolix sodium”) to the patient having hepatic impairment classified as Child-Pugh B, and
- continuing said oral administration to the patient having hepatic impairment classified as Child-Pugh B once daily for up to 6 months;
- wherein said method manages the moderate to severe pain associated with endometriosis in the patient.
Dependencies are inferred from the claim text.